Jean-Claude J M, Reilly L M, Stoney R J, Messina L M
University of California-San Francisco, 94143, USA.
J Vasc Surg. 1999 May;29(5):902-12. doi: 10.1016/s0741-5214(99)70218-1.
As endovascular stent graft repair of infrarenal abdominal aortic aneurysms (AAAs) becomes more common, an increasing proportion of patients who undergo open operation will have juxtarenal aneurysms (JR-AAAs), which necessitate suprarenal crossclamping, suprarenal aneurysms (SR-AAAs), which necessitate renal artery reconstruction, or aneurysms with associated renal artery occlusive disease (RAOD), which necessitate repair. To determine the current results of the standard operative treatment of these patterns of pararenal aortic aneurysms, we reviewed the outcome of 257 consecutive patients who underwent operation for JR-AAAs (n = 122), SR-AAAs (n = 58), or RAOD (n = 77).
The patients with SR-AAAs and RAOD were younger (67.5 +/- 8.8 years) than were the patients with JR-AAAs (70.5 +/- 8.3 years), and more patients with RAOD were women (43% vs 21% for JR-AAAs and SR-AAAs). The patient groups were similar in the frequency of coronary artery and pulmonary disease and in most risk factors for atherosclerosis, except hypertension, which was more common in the RAOD group. Significantly more patients with RAOD had reduced renal function before surgery (51% vs 23%). Supravisceral aortic crossclamping (above the superior mesenteric artery or the celiac artery) was needed more often in patients with SR-AAAs (52% vs 39% for RAOD and 17% for JR-AAAs). Seventeen patients (7%) had undergone a prior aortic reconstruction. The most common renal reconstruction for SR-AAA was reimplantation (n = 37; 64%) or bypass grafting (n = 12; 21%) and for RAOD was transaortic renal endarterectomy (n = 71; 92%). Mean AAA diameter was 6.7 +/- 2.1 cm and was larger in the JR-AAA (7.1 +/- 2.1 cm) and SR-AAA (6.9 +/- 2.1 cm) groups as compared with the RAOD group (5.9 +/- 1.7 cm).
The overall mortality rate was 5.8% (n = 15) and was the same for all the groups. The mortality rate correlated (P <.05) with hematologic complications (bleeding) and postoperative visceral ischemia or infarction but not with aneurysm group or cardiac, pulmonary, or renal complications. Renal ischemia duration averaged 31.6 +/- 21.6 minutes and was longer in the SR-AAA group (43.6 +/- 38.9 minutes). Some postoperative renal function loss occurred in 104 patients (40.5%), of whom 18 (7.0%) required dialysis. At discharge or death, 24 patients (9.3%) still had no improvement in renal function and 11 of those patients (4.3%) remained on dialysis. Postoperative loss of renal function correlated (P <.05) with preoperative abnormal renal function and duration of renal ischemia but not with aneurysm type, crossclamp level, or type of renal reconstruction.
These results showed that pararenal AAA repair can be performed safely and effectively. The outcomes for all three aneurysm types were similar, but there was an increased risk of loss of renal function when preoperative renal function was abnormal. These data provide a benchmark for expected treatment outcomes in patients with these patterns of pararenal aortic aneurysmal disease that currently can only be managed with open repair.
随着肾下腹主动脉瘤(AAA)的血管内支架植入修复术越来越普遍,接受开放手术的患者中,需要进行肾上交叉钳夹的近肾动脉瘤(JR - AAA)、需要进行肾动脉重建的肾上腺动脉瘤(SR - AAA)或伴有肾动脉闭塞性疾病(RAOD)且需要修复的动脉瘤患者比例不断增加。为了确定这些肾旁主动脉瘤模式的标准手术治疗的当前结果,我们回顾了连续257例接受手术治疗的JR - AAA(n = 122)、SR - AAA(n = 58)或RAOD(n = 77)患者的结局。
SR - AAA和RAOD患者比JR - AAA患者年轻(67.5±8.8岁 vs 70.5±8.3岁),RAOD患者中女性更多(43%,而JR - AAA和SR - AAA患者中女性占21%)。除高血压在RAOD组更常见外,各患者组在冠状动脉疾病和肺部疾病的发生率以及大多数动脉粥样硬化危险因素方面相似。术前肾功能减退的RAOD患者明显更多(51% vs 23%)。SR - AAA患者更常需要进行内脏上主动脉交叉钳夹(在肠系膜上动脉或腹腔动脉上方)(52%,RAOD患者为39%,JR - AAA患者为17%)。17例患者(7%)曾接受过主动脉重建。SR - AAA最常见的肾重建方法是再植入(n = 37;64%)或搭桥移植(n = 12;21%),RAOD最常见的是经主动脉肾动脉内膜切除术(n = 71;92%)。AAA平均直径为6.7±2.1 cm,JR - AAA组(7.1±2.1 cm)和SR - AAA组(6.9±2.1 cm)的直径大于RAOD组(5.9±1.7 cm)。
总死亡率为5.8%(n = 15),所有组相同。死亡率与血液学并发症(出血)及术后内脏缺血或梗死相关(P <.05),但与动脉瘤类型、心脏、肺部或肾脏并发症无关。肾缺血持续时间平均为31.6±21.6分钟,SR - AAA组更长(43.6±38.9分钟)。104例患者(40.5%)术后出现一定程度的肾功能丧失,其中18例(7.0%)需要透析。出院或死亡时,24例患者(9.3%)肾功能仍未改善,其中11例(4.3%)仍在接受透析。术后肾功能丧失与术前肾功能异常及肾缺血持续时间相关(P <.05),但与动脉瘤类型、交叉钳夹水平或肾重建类型无关。
这些结果表明,肾旁AAA修复术可安全有效地进行。三种动脉瘤类型的结局相似,但术前肾功能异常时肾功能丧失的风险增加。这些数据为目前只能通过开放修复治疗的这些肾旁主动脉瘤疾病模式患者的预期治疗结局提供了一个基准。